Objective To investigate the prevalence of behavior problems in twins aged 10-16 years, and to provide a theoretical basis for the prevention and treatment of twins’ behavior problems. Methods Sixty-four pairs of twins aged 10-16 years in Chengdu city participated in this study. The Child Behavior Checklist (CBCL), completed by parents, was used to assess behavior problems. The prevalence of behavior problems in twins and the distribution characteristics for boys and girls and zygosities were estimated. Results The prevalence of behavior problems in the twins in this study was 6.25%. This was lower than the prevalence in a nationwide non-twins epidemiologic survey (P=0.0045). No significant difference was found in the prevalence of behavior problems between boys and girls and between different zygosities (P=0.891; P=0.258). Social problems were the main behavior problems noted in these twins, accounting for 38%. Conclusions The prevalence of behavior problems in twins aged 10-16 years is lower than that of non-twins. Social problems are the most common behavior problems in the twins in this study.
The CONSORT extension for reporting N-of-1 trials (CENT 2015) is designed to guide N-of-1 and series N-of-1 reporting. This study introduced the terminology (period, block or pair, sequence, washout period, and run-in period), the scope, the checklist and the diagram of CENT 2015 and demonstrated the complete guide frame for N-of-1, and thus to provide reference for relevant studies and improve the reporting quality of N-of-1 in China.
The preferred reporting items for comprehensive evaluation of Chinese patent medicine (PRICE-CPM) were developed, and comprised six domains, 21 items and 72 sub-items. The EQUATOR collaboration network for the formulation and revision of reporting specifications was referred to and the final report list items were established by adopting the literature analysis method, the expert committee discussion and the Delphi method, and considering the characteristics of CPM evaluation.
Health Technology Assessment International (HTAi), in conjunction with the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), initiated a joint Task Force and published guideline and a checklist for deliberative processes for health technology assessment (HTA). Currently, there is a lack of guidance for designing and implementing deliberative processes of HTA in China, so this paper performs a detailed interpretation of the guideline and checklist, with a view to providing a reference for China's HTA and deliberative process, in order to promote the dissemination and application of the HTA methodology, and advance the construction of domestic HTA deliberative processes capacity and institutional mechanism.